Abstract
Purpose: Metabolic impairment is one key contributor to heart failure (HF) pathogenesis and progression. The major causes of HF, coronary heart disease (CHD), dilated cardiomyopathy (DCM), and valvular heart disease (VHD) remains poorly characterized in patients with HF from the view of metabolic profile. We sought to determine metabolic differences in CHD-, VHD-, and DCM-induced HF patients and identify significantly altered metabolites and their correlations. Procedure: In this study, a total of 96 HF cases and 97 controls were enrolled. The contents of 23 amino acids and 26 carnitines in fasting plasma were measured by a targeted liquid chromatography and mass spectrometry (LC-MS) approach. Results: Nine metabolites (Histidine, Arginine, Citrulline, Glutamine, Valine, hydroxyhexadecenyl-carnitine, acylcarnitine C22, hydroxytetradecanoyl-carnitine, and carnitine) were found to be related with the occurrence of HF. Arginine, Glutamine and hydroxytetradecanoyl-carnitine could effectively distinguish CHD and DCM patients, and hydroxytetradecanoyl-carnitine and aspartic acid were able to classify CHD and VHD cohorts. Conclusion: This study indicated that circulating amino acids and long-chain acylcarnitine levels were closely associated with progression of heart failure. Monitoring these metabolic alterations by LC-MS may help the differentiation of CHD, VHD, and DCM in the early stage, and provide new diagnostics targets or therapeutic interventions.
Introduction
Heart failure (HF) is a global health crisis, representing the common end-stage of several distinct cardiovascular conditions, primarily Coronary Heart Disease (CHD), Dilated Cardiomyopathy (DCM), and Valvular Heart Disease (VHD). While clinical diagnosis of HF is established, pinpointing the specific underlying etiology early in the disease progression remains challenging. This distinction is critical for tailoring therapeutic interventions.
It is well-established that a failing heart undergoes "metabolic remodeling," shifting its fuel preference from fatty acids toward glucose and ketones. However, the specific metabolic signatures that differentiate CHD-, DCM-, and VHD-induced heart failure have remained poorly understood. This study aims to identify blood-based metabolic biomarkers that can detect HF and distinguish between its primary causes.
Methods and Materials
The researchers utilized targeted Liquid Chromatography-Mass Spectrometry (LC-MS) to analyze fasting plasma samples from a clinical cohort at the First Affiliated Hospital of Dalian Medical University. The study focused on 49 specific small molecules: 23 amino acids and 26 carnitines.
Statistical analysis included Principal Component Analysis (PCA) for unsupervised clustering and Partial Least Squares Discriminant Analysis (PLS-DA) to identify metabolites with the highest Variable Importance in Projection (VIP) scores. Diagnostic accuracy was evaluated using Receiver Operating Characteristic (ROC) curves to determine the Area Under the Curve (AUC) for key metabolites.
Results
Metabolic Signatures of Heart Failure
The analysis revealed a significant systemic metabolic shift in HF patients compared to healthy controls. A primary finding was the "fatty acid bottleneck," characterized by significantly higher levels of long-chain acylcarnitines (e.g., C14-OH and C16:1-OH). This suggests impaired mitochondrial processing of long-chain fatty acids, leading to an accumulation of metabolic intermediates in the blood.
Conversely, several amino acids, including Histidine, Glutamine, and Valine, were significantly depleted in HF patients. This likely reflects a state of high energy demand where the body scavenges these amino acids to fuel the TCA cycle, attempting to compensate for failing fatty acid metabolism.
Diagnostic and Etiological Differentiation
Nine core metabolites were identified as significant HF markers. Five of these—Histidine, Citrulline, Glutamine, Valine, and Carnitine (C0)—demonstrated excellent diagnostic accuracy with AUC values exceeding 0.80.
Crucially, the study found that metabolic profiles could distinguish the underlying cause of HF:
- CHD vs. DCM: These etiologies could be effectively distinguished using Arginine, Glutamine, and hydroxytetradecanoyl-carnitine (C14-OH). Notably, Arginine (a precursor to the vasodilator Nitric Oxide) was higher in CHD patients, suggesting differing levels of vascular stress.
- CHD vs. VHD: These cohorts were successfully classified using C14-OH and Aspartic acid.
Discussion and Conclusion
This research demonstrates that circulating amino acids and long-chain acylcarnitine levels are closely associated with the progression and etiology of heart failure. The findings move clinical diagnostics closer to "metabolic phenotyping," where blood tests could assist cardiologists in identifying not just the presence of heart failure, but its specific cause.
Limitations of the study include a relatively small sample size for the VHD and DCM subgroups and the cross-sectional nature of the data. Future longitudinal studies are required to track how these metabolic markers evolve with treatment and disease progression. Nonetheless, monitoring these metabolic alterations via LC-MS offers a promising avenue for early differentiation and the development of new therapeutic targets in cardiovascular medicine.
Summary updated